The β-Lactamase Inhibitor Boronic Acid Derivative SM23 as a New Anti-Pseudomonas aeruginosa Biofilm
is a Gram-negative nosocomial pathogen, often causative agent of severe device-related infections, given its great capacity to form biofilm. finely regulates the expression of numerous virulence factors, including biofilm production, by Quorum Sensing (QS), a cell-to-cell communication mechanism use...
Saved in:
Published in | Frontiers in microbiology Vol. 11; p. 35 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Switzerland
Frontiers Media S.A
07.02.2020
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | is a Gram-negative nosocomial pathogen, often causative agent of severe device-related infections, given its great capacity to form biofilm.
finely regulates the expression of numerous virulence factors, including biofilm production, by Quorum Sensing (QS), a cell-to-cell communication mechanism used by many bacteria. Selective inhibition of QS-controlled pathogenicity without affecting bacterial growth may represent a novel promising strategy to overcome the well-known and widespread drug resistance of
. In this study, we investigated the effects of SM23, a boronic acid derivate specifically designed as β-lactamase inhibitor, on biofilm formation and virulence factors production by
. Our results indicated that SM23: (1) inhibited biofilm development and production of several virulence factors, such as pyoverdine, elastase, and pyocyanin, without affecting bacterial growth; (2) decreased the levels of 3-oxo-C
-HSL and C
-HSL, two QS-related autoinducer molecules, in line with a dampened
/
system; (3) failed to bind to bacterial cells that had been preincubated with
conditioned medium; and (4) reduced both biofilm formation and pyoverdine production by
onto endotracheal tubes, as assessed by a new
model closely mimicking clinical settings. Taken together, our results indicate that, besides inhibiting β-lactamase, SM23 can also act as powerful inhibitor of
biofilm, suggesting that it may have a potential application in the prevention and treatment of biofilm-associated
infections. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Edited by: Silvia Buroni, University of Pavia, Italy Reviewed by: Mona I. Shaaban, Mansoura University, Egypt; Rodolfo García-Contreras, National Autonomous University of Mexico, Mexico These authors have contributed equally to this work This article was submitted to Antimicrobials, Resistance and Chemotherapy, a section of the journal Frontiers in Microbiology |
ISSN: | 1664-302X 1664-302X |
DOI: | 10.3389/fmicb.2020.00035 |